Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Clinical course

From: Pediatric chronic myeloid leukemia with inv(3)(q21q26.2) and T lymphoblastic transformation: a case report

Day of TKI treatment Clinical event qPCR BCR/ABL, Blood (IS units) qPCR BCR/ABL, Marrow (IS units) T lymphoblasts, Marrow
−1 CML diagnosis confirmed 44 %   9 %
1 Started imatinib 500 mg daily    
22   58 %   
25    65 % 1 %
29   69 %   
34   50 %   
41   67 %   
49 Started dasatinib 100 mg daily 56 %   
54   52 % 52 % 0.02 %
64   28 %   
68   22 %   
92   4.3 %   
  1. Timeline of clinical events, BCR-ABL1 transcript levels detected by qPCR in the blood and bone marrow, and percentage of T lymphoblasts in the bone marrow as measured by flow cytometry. Timeline is reported relative to day 1 of treatment with imatinib. TKI tyrosine kinase inhibitor, qPCR quantitative polymerase chain reaction, IS international standard units